Using real-world data to evaluate biosimilar switching
Pharmacoepidemiol Drug Saf
.
2020 Jul;29(7):814-816.
doi: 10.1002/pds.4899.
Epub 2019 Nov 6.
Authors
Sarah K Dutcher
1
,
Efe Eworuke
1
,
Michael D Blum
1
,
Robert Ball
1
Affiliation
1
Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.
PMID:
31692176
DOI:
10.1002/pds.4899
No abstract available
Publication types
Comment
MeSH terms
Biosimilar Pharmaceuticals*
Drug Substitution
Infliximab
Substances
Biosimilar Pharmaceuticals
Infliximab